Latest Insider Transactions at Athira Pharma, Inc. (ATHA)
This section provides a real-time view of insider transactions for Athira Pharma, Inc. (ATHA). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Athira Pharma, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Athira Pharma, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jun 29
2022
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
270,000
+6.81%
|
$540,000
$2.99 P/Share
|
|
Jun 28
2022
|
Hans Moebius Chief Medical Officer |
BUY
Open market or private purchase
|
Direct |
10,000
+15.88%
|
$20,000
$2.88 P/Share
|
|
Jun 23
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
SELL
Open market or private sale
|
Direct |
2,614
-4.33%
|
$5,228
$2.69 P/Share
|
|
Jun 23
2022
|
Rachel Lenington COO and CDO |
SELL
Open market or private sale
|
Direct |
4,193
-41.93%
|
$8,386
$2.69 P/Share
|
|
Jun 23
2022
|
Mark James Litton President and CEO |
SELL
Open market or private sale
|
Direct |
7,960
-5.83%
|
$15,920
$2.69 P/Share
|
|
Jun 23
2022
|
Glenna Mileson Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,614
-2.34%
|
$5,228
$2.69 P/Share
|
|
Jun 23
2022
|
Mark Worthington General Counsel and CCO |
SELL
Open market or private sale
|
Direct |
2,614
-12.04%
|
$5,228
$2.69 P/Share
|
|
Jun 22
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+14.22%
|
-
|
|
Jun 22
2022
|
Rachel Lenington COO and CDO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+50.0%
|
-
|
|
Jun 22
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
20,000
+12.78%
|
-
|
|
Jun 22
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+8.21%
|
-
|
|
Jun 22
2022
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+18.88%
|
-
|
|
Jun 22
2022
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
10,000
+31.53%
|
-
|
|
Jun 08
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
2,500
+4.73%
|
$2,500
$1.35 P/Share
|
|
May 18
2022
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
757
+0.65%
|
$5,299
$7.06 P/Share
|
|
May 18
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,721
+1.66%
|
$12,047
$7.06 P/Share
|
|
May 18
2022
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,699
+4.9%
|
$11,893
$7.06 P/Share
|
|
May 18
2022
|
Mark Worthington General Counsel and CCO |
BUY
Grant, award, or other acquisition
|
Direct |
3,396
+22.48%
|
$23,772
$7.06 P/Share
|
|
May 18
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
243
+0.51%
|
$1,701
$7.06 P/Share
|
|
Apr 11
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,000
+2.91%
|
$30,000
$10.64 P/Share
|
|
Mar 31
2022
|
Kelly A Romano |
BUY
Open market or private purchase
|
Direct |
8,000
+49.03%
|
$104,000
$13.11 P/Share
|
|
Feb 18
2022
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,152
+6.21%
|
$3,152
$1.19 P/Share
|
|
Jan 04
2022
|
Glenna Mileson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,305
+6.1%
|
$6,305
$1.35 P/Share
|
|
Nov 18
2021
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
885
+0.76%
|
$10,620
$12.51 P/Share
|
|
Nov 18
2021
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Grant, award, or other acquisition
|
Direct |
96
+0.22%
|
$1,152
$12.51 P/Share
|
|
Nov 18
2021
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
829
+2.58%
|
$9,948
$12.51 P/Share
|
|
Nov 18
2021
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
931
+1.02%
|
$11,172
$12.51 P/Share
|
|
Aug 17
2021
|
Mark James Litton President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,440
+30.51%
|
$50,440
$1.35 P/Share
|
|
Jul 21
2021
|
Hans Moebius Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
28,372
+40.18%
|
$28,372
$1.35 P/Share
|
|
Jun 15
2021
|
John M Fluke Jr |
BUY
Other acquisition or disposition
|
Direct |
1,000
+0.69%
|
-
|
|
Jun 15
2021
|
John M Fluke Jr |
SELL
Other acquisition or disposition
|
Indirect |
3,000
-44.57%
|
-
|
|
Jun 10
2021
|
Glenna Mileson Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,305
+6.56%
|
$6,305
$1.35 P/Share
|
|
Jun 08
2021
|
Kevin Church CHIEF SCIENTIFIC OFFICER |
BUY
Exercise of conversion of derivative security
|
Direct |
3,152
+6.67%
|
$3,152
$1.04 P/Share
|
|
May 18
2021
|
Mark James Litton President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
867
+1.33%
|
$12,138
$14.45 P/Share
|
|
May 18
2021
|
Hans Moebius Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
2,055
+50.0%
|
$28,770
$14.45 P/Share
|
|
May 18
2021
|
Glenna Mileson Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
1,554
+1.83%
|
$21,756
$14.45 P/Share
|
|
Feb 03
2021
|
John M Fluke Jr |
BUY
Exercise of conversion of derivative security
|
Direct |
29,003
+8.91%
|
$29,003
$1.27 P/Share
|
|
Jan 25
2021
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
311,111
+8.33%
|
$6,844,442
$22.5 P/Share
|
|
Sep 22
2020
|
Perceptive Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
1,058,824
+25.37%
|
$18,000,008
$17.0 P/Share
|
|
Sep 22
2020
|
Perceptive Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
1,644,785
+44.44%
|
-
|
|
Sep 18
2020
|
Rtw Investments, LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
750,000
+21.94%
|
$12,750,000
$17.0 P/Share
|
|
Sep 18
2020
|
Rtw Investments, LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,535,131
+44.44%
|
-
|